Cover Image

PAPERBACK
$43.50



View/Hide Left Panel

Pathogen (Target Population)

Type of Vaccine

Time to Licensure (years)

Time After Licensure to Adoption (years)

Total Time to Steady State of Vaccine Use (years)

Delay of Vaccination Benefits (years)

Total Time to Steady-State Yield of Benefits (years)

Mycobacterium leprae

(Immunoprophylactic: all children in endemic areas. Immuno therapeutic: all recently infected individuals)

Armadillo-derived M. leprae

10

5

15

6

21

Neisseria meningitidis

(Infants, 3 to 6 months)

Conjugated capsular polysaccharides, Groups A,C,Y, and W135

5

5

10

3

13

Parainfluenza viruses

(Infants)

Trivalent, subunit vaccine (which must contain fusion proteins)

5

5

10

1

11

Plasmodium spp.

(All infants at risk, military personnel, travelers)

Plasmodium falciparum, synthetic or recombinant sporozoite antigen preparation

6.5

2

8.5

3

11.5

Multivalent synthetic or recombinant sporozoite antigen preparation (P. falciparum, P. vivax, P. ovale, P. malariae)

9

2

11

3

14

Rabies virus (Individuals at high risk, plus post-exposure prophylaxis) (As above)

Vero cell

3

3.5

6.5

1

7.5

Glycoprotein produced by rDNA technology in mammalian cells

3

3.5

6.5

1

7.5

(Birth cohort in areas of high risk)

Attenuated live vector virus containing gene for protective glycoprotein antigen

10

2

12

10

22



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement